PET studies of 18F-memantine in healthy volunteers

Nuclear Medicine and Biology

Volumn 29, Issue 2, 2002, Pages 227-231

  Ametamey, S M ^a   Bruehlmeier, M ^a   Kneifel, S ^b   Kokic, M ^a   Honer, M ^a   Arigoni, M ^b   Buck, A ^b   Burger, C ^b   Samnick, S ^d   Quack, G ^c   Schubiger, P A ^a  

^a Center for Radiopharmaceutical Science of ETH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

18F memantine; NMDA receptor; PET

Indexed keywords

MEMANTINE F 18; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1 AMINO 3 FLUOROMETHYL 5 METHYLADAMANTANE; 1-AMINO-3-FLUOROMETHYL-5-METHYLADAMANTANE; DRUG DERIVATIVE; MEMANTINE;

ADULT; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; COMPARTMENT MODEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG UPTAKE; FRONTAL CORTEX; GRAY MATTER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RECEPTOR DENSITY; WHITE MATTER; BLOOD; BRAIN; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; RADIOASSAY; REFERENCE VALUE; SCINTISCANNING;

ADULT; BRAIN; HUMANS; MALE; MEMANTINE; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, N-METHYL-D-ASPARTATE; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036007564     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00293-1     Document Type: Article

References (22)

1. A new look at the statistical model identification IEEE
2. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor J
3. 18F]methyl-MK-801, a potential NMDA receptor complex radioligand
4. Different binding affinities of NMDA receptor channel blockers in various brain regions-Indication of NMDA receptor heterogeneity
5. Glutamate neurotoxicity and diseases of the nervous system
6. Selective reduction of quisqualate (AMPA) receptors in Alzheimer cerebellum
7. Effects of temporal sampling, glucose metabolic rates, and disruption of the blood brain barrier on the FDG model with and without a vascular compartment, Studies in human brain tumours with PET
8. Glycine potentiates NMDA response in cultured mouse brain neurones
9. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography
10. Graphical analysis of reversible radioligand binding from time-activity measurements applied to N-11C-methyl-(-)cocaine: PET studies in human subjects
11. A JAVA environment for medical image data analysis, Initial application for brain PET quantification
12. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography
13. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist
14. First SPET images of glutamate (NMDA) receptor activation in vivo in cerebral ischaemia
15. Patch clamp studies on the kinetics and selectivity of NMDA receptor antagonism by memantine
16. Anticonvulsant activity of the NMDA antagonists, D(-)4-(3-phosphonopropyl)piperazine-2-carboxylic acid (D-CPP) and D(-)(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (D-CPP-ene) in a rodent and primate model of reflex epilepsy
17. Excitotoxicity and the NMDA receptor
18. 18F]-fluoromethyl-5-methyl adamantane: A potential ligand for mapping the NMDA receptor-complex
19. 18F-MEM): A potential radioligand for mapping the NMDA-receptor complex
20. Synthesis and evaluation of new 18F-labelled thienylcyclohexylpiperidine (TCP) analogues as radioligands for the NMDA receptor-channel complex
21. PCP and sigma receptors in brain are not altered after repeated exposure to PCP in humans
22. NMDA receptor losses in putamen from patients with Huntington's disease